Calico (company): Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{short description|American research and development company}} | |||
{{Use mdy dates|date=October 2023}} | |||
[[File:Calico_LLC_logo.svg|thumb|right|Calico LLC logo]] | |||
Calico | '''Calico LLC''' is an American [[research and development]] company founded in 2013 by [[Google]] and [[Arthur D. Levinson]]. The company focuses on the study of [[aging]] and associated diseases, with the aim of extending the human [[lifespan]]. | ||
== | ==History== | ||
Calico was announced on September 18, 2013, by [[Larry Page]], then CEO of Google, in a post on the official Google blog. The company was established as a subsidiary of [[Alphabet Inc.]], Google's parent company, and is headquartered in [[South San Francisco, California]]. | |||
Calico | The name "Calico" is an abbreviation of "California Life Company." The company was founded with the mission to "harness advanced technologies to increase our understanding of the biology that controls lifespan." | ||
== | ==Research Focus== | ||
Calico's research is primarily focused on understanding the biological mechanisms of aging and developing interventions to address age-related diseases. The company employs a multidisciplinary approach, combining [[genomics]], [[bioinformatics]], and [[molecular biology]] to explore the underlying causes of aging. | |||
Calico | ===Aging and Longevity=== | ||
Aging is a complex biological process that involves the gradual deterioration of cellular and molecular functions. Calico aims to identify the genetic and environmental factors that contribute to aging and to develop therapies that can slow down or reverse these processes. | |||
== | ===Age-related Diseases=== | ||
Calico's research also targets diseases that are prevalent in older populations, such as [[cancer]], [[neurodegenerative diseases]], and [[cardiovascular diseases]]. By understanding the common pathways that lead to these conditions, Calico hopes to develop treatments that can improve healthspan as well as lifespan. | |||
Calico | ==Collaborations== | ||
Calico has established several partnerships with leading academic institutions and biotechnology companies to advance its research. Notable collaborations include partnerships with [[AbbVie]], a global biopharmaceutical company, to develop and commercialize new therapies for age-related diseases. | |||
== | ==Leadership== | ||
The company is led by Arthur D. Levinson, who serves as the CEO. Levinson is a prominent figure in the biotechnology industry, having previously served as the CEO of [[Genentech]]. | |||
==Facilities== | |||
Calico's research facilities are located in South San Francisco, where the company conducts its laboratory and clinical research. The facilities are equipped with state-of-the-art technology to support its scientific endeavors. | |||
==Related pages== | |||
* [[Aging]] | * [[Aging]] | ||
* [[ | * [[Biotechnology]] | ||
* [[ | * [[Genomics]] | ||
* [[ | * [[Lifespan]] | ||
* [[Alphabet Inc.]] | |||
[[Category:Biotechnology companies of the United States]] | [[Category:Biotechnology companies of the United States]] | ||
[[Category:Companies based in South San Francisco, California]] | |||
[[Category:Companies | [[Category:Alphabet Inc.]] | ||
[[Category: | [[Category:Research and development organizations]] | ||
[[Category: | |||
Latest revision as of 11:17, 15 February 2025
American research and development company
Calico LLC is an American research and development company founded in 2013 by Google and Arthur D. Levinson. The company focuses on the study of aging and associated diseases, with the aim of extending the human lifespan.
History[edit]
Calico was announced on September 18, 2013, by Larry Page, then CEO of Google, in a post on the official Google blog. The company was established as a subsidiary of Alphabet Inc., Google's parent company, and is headquartered in South San Francisco, California.
The name "Calico" is an abbreviation of "California Life Company." The company was founded with the mission to "harness advanced technologies to increase our understanding of the biology that controls lifespan."
Research Focus[edit]
Calico's research is primarily focused on understanding the biological mechanisms of aging and developing interventions to address age-related diseases. The company employs a multidisciplinary approach, combining genomics, bioinformatics, and molecular biology to explore the underlying causes of aging.
Aging and Longevity[edit]
Aging is a complex biological process that involves the gradual deterioration of cellular and molecular functions. Calico aims to identify the genetic and environmental factors that contribute to aging and to develop therapies that can slow down or reverse these processes.
[edit]
Calico's research also targets diseases that are prevalent in older populations, such as cancer, neurodegenerative diseases, and cardiovascular diseases. By understanding the common pathways that lead to these conditions, Calico hopes to develop treatments that can improve healthspan as well as lifespan.
Collaborations[edit]
Calico has established several partnerships with leading academic institutions and biotechnology companies to advance its research. Notable collaborations include partnerships with AbbVie, a global biopharmaceutical company, to develop and commercialize new therapies for age-related diseases.
Leadership[edit]
The company is led by Arthur D. Levinson, who serves as the CEO. Levinson is a prominent figure in the biotechnology industry, having previously served as the CEO of Genentech.
Facilities[edit]
Calico's research facilities are located in South San Francisco, where the company conducts its laboratory and clinical research. The facilities are equipped with state-of-the-art technology to support its scientific endeavors.
